Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report

Amina Rezkallah; Olivier Loria; Thibaud Mathis; Samuel Chacun; Philippe Denis; Laurent Kodjikian

doi:10.1159/000527672

Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report

Case Rep Ophthalmol. 2022 Dec 16;13(3):1024-1029. doi: 10.1159/000527672. eCollection 2022 Sep-Dec.

Authors

Amina Rezkallah^{1

2}, Olivier Loria^{1

2}, Thibaud Mathis^{1

2}, Samuel Chacun¹, Philippe Denis¹, Laurent Kodjikian^{1

2}

Affiliations

¹ Service d'Ophtalmologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
² UMR-CNRS 5510 Matéis, Université Claude Bernard Lyon 1, Villeurbanne, France.

Abstract

Diabetic macular edema (DME) is now a well-known condition for which a number of treatments have been shown to be effective. Intraocular corticosteroids are part of this therapeutic arsenal but are sometimes responsible for ocular hypertension. We describe here the case of a 60-year-old man with a history of bilateral DME who received an intravitreal injection of 190 µg fluocinolone acetonide (FAc) (ILUVIEN^®, Alimera Sciences, Alpharetta, GA, USA) who presented a persistent ocular hypertension in one eye despite FAc removal by pars plana vitrectomy and was successfully managed by Preserflo^® microshunt surgery.

Keywords: Fluocinolone acetonide implant; Microinvasive bleb surgery; Steroid-induced ocular hypertension.

Publication types

Case Reports